GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...

GSK plc, aka GlaxoSmithKline, is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...